Colchicine for Autoimmune and Subacute Thyroiditis

Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-70
SponsorMansoura University

About this trial

Thyroiditis includes inflammatory thyroid disorders such as Hashimoto's thyroiditis and subacute thyroiditis. These conditions may cause thyroid pain, neck tenderness, elevated inflammatory markers, thyroid dysfunction, fatigue, and recurrence. Current management includes observation, symptomatic treatment, nonsteroidal anti-inflammatory drugs, and corticosteroids. Although corticosteroids may be effective, relapse after tapering and treatment-related adverse effects remain limitations. Colchicine is hypothesized to reduce inflammatory activity and may improve biochemical and clinical recovery. This study will evaluate the efficacy and safety of low-dose colchicine compared with corticosteroid therapy and supportive care in adults with autoimmune or subacute thyroiditis.

Eligibility criteria

Qualifiers

Age 18 to 70 years

Newly diagnosed Hashimoto's thyroiditis or Subacute thyroiditis

Diagnosis confirmed clinically, biochemically, and ultrasonographically

Ability to provide written informed consent

Disqualifiers

Pregnancy or breastfeeding

Severe renal impairment

Severe hepatic disease

Cytopenia

Trial design

Treatments tested in this trial

  • colchicine
  • Prednisolone
  • NSAID

Treatment groups

300 Participants
are divided into 3 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Mansoura University

Lead sponsor

Saudi German Hospital - Madinah

Collaborator